Global Server Security Market To Reach USD 60,885.1 Million By 2035, Driven By AI And Industry 4.0 Innovations | Future Market Insights Inc.
The global sales of power capacitors are estimated to be worth USD 15,349.0 million in 2024 and are anticipated to reach a value of USD 25,995.4 million by 2034. Sales are projected to rise at a CAGR ...
Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript
Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.71. Thomas Larsen: Welcome to the Q4 and Full Year 2024 Conference Call ...
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...
Equillium announces itolizumab study achieves secondary endpoint
Equillium (EQ) and Biocon announced topline results from the Phase 2 study evaluating itolizumab in the treatment of moderate to severe ...
Financial Post4d
Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute ... to the Phase II idiopathic pulmonary fibrosis (IPF) study, ...
PharmiWeb4d
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 ...
Morningstar4d
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
1Boehringer Ingelheim (2024) Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study. Accessed January 2025. Available at: https://www.boehringer-ingelheim ...
Yahoo Finance4d
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint ... idiopathic pulmonary fibrosis (IPF) study, with overall adverse events ...
Bristol Myers Squibb Cancer Treatment Misses Primary Endpoint in Trial
Bristol Myers Squibb said it is disappointed with the outcome of a study that examined whether one of its drugs could be used to treat a certain type of skin cancer. The drug, Opdualag, didn't meet ...
Morningstar4d
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
The Precision-T study met the protocol-specified primary endpoint of a statistically significant improvement in survival free of moderate-to-severe chronic graft versus host disease (cGvHD ...
Finanznachrichten4d
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint ... idiopathic pulmonary fibrosis (IPF) study, with overall adverse events comparable ...